Cargando…

Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis

The 2019 novel coronavirus (COVID-19) pandemic has placed a significant strain on hepatitis programs and interventions (screening, diagnosis, and treatment) at a critical moment in the context of hepatitis C virus (HCV) elimination. We sought to quantify changes in Direct Acting Antiviral (DAA) util...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shakeri, Ahmad, Konstantelos, Natalia, Chu, Cherry, Antoniou, Tony, Feld, Jordan, Suda, Katie J., Tadrous, Mina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310258/ https://www.ncbi.nlm.nih.gov/pubmed/34372520 http://dx.doi.org/10.3390/v13071314

Ejemplares similares

The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada
por: Chu, Cherry, et al.
Publicado: (2023)

Effects of the July 2018 worldwide valsartan recall and shortage on global trends in antihypertensive medication use: a time-series analysis in 83 countries
por: Choi, Yuna, et al.
Publicado: (2023)

Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
por: Antoniou, Tony, et al.
Publicado: (2023)

Correction: Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
por: Antoniou, Tony, et al.
Publicado: (2023)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Major Shifts in Acid Suppression Drug Utilization After the 2019 Ranitidine Recalls in Canada and United States
por: Gunning, Robin, et al.
Publicado: (2023)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
por: Casey, Julia L., et al.
Publicado: (2019)

HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy
por: Álvarez, Beatriz, et al.
Publicado: (2022)

Mapping global trends in vaccine sales before and during the first wave of the COVID-19 pandemic: a cross-sectional time-series analysis
por: Zeitouny, Seraphine, et al.
Publicado: (2021)

P1096: TREATMENT OF HEPATITIS C-ASSOCIATED MARGINAL ZONE LYMPHOMA(HCV+LMZ) WITH DIRECT-ACTING ANTIVIRAL DRUGS (DAAS)
por: Lepkov, Sergey, et al.
Publicado: (2023)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV
por: Morsica, Giulia, et al.
Publicado: (2022)

HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly
por: Brozzetti, Stefania, et al.
Publicado: (2021)

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections
por: Izhari, Mohammad Asrar
Publicado: (2023)

Successful Treatment of Hepatitis C Virus Infection Using Direct-Acting Antiviral Agents (DAAs) in Adolescents with Kidney Transplantation: A Case Series
por: Ambarsari, Cahyani Gita, et al.
Publicado: (2020)

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
por: Walker, David R., et al.
Publicado: (2015)

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation
por: Grottenthaler, Julia M., et al.
Publicado: (2018)

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
por: Millian, Daniel, et al.
Publicado: (2023)

Trends and duration of antibacterial drug supply chain issues in the United States, January 2017–June 2022
por: Suda, Katie, et al.
Publicado: (2023)

Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden
por: Frisk, P., et al.
Publicado: (2018)

Comparison of Healthcare Utilization Between Telemedicine and Standard Care: A Propensity-Score Matched Cohort Study Among Individuals With Chronic Psychotic Disorders in Ontario, Canada
por: Shakeri, Ahmad, et al.
Publicado: (2022)

Virtual care use during the COVID-19 pandemic and its impact on healthcare utilization in patients with chronic disease: A population-based repeated cross-sectional study
por: Stamenova, Vess, et al.
Publicado: (2022)

The Association Between Telemedicine Use and Changes in Health Care Usage and Outcomes in Patients With Congestive Heart Failure: Retrospective Cohort Study
por: Chu, Cherry, et al.
Publicado: (2022)

Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections
por: Welzel, Tania M., et al.
Publicado: (2019)

Global trends in antidepressant, atypical antipsychotic, and benzodiazepine use: A cross-sectional analysis of 64 countries
por: Alabaku, Orges, et al.
Publicado: (2023)

Identifying Different Mutation Sites Leading to Resistance to the Direct-Acting Antiviral (DAA) Sofosbuvir in Hepatitis C Virus Patients from Egypt
por: Shoun, Aly Atef, et al.
Publicado: (2022)

ADAM10 Gene Polymorphism and Its Relationship to Hepatocellular Carcinoma in Egyptian HCV Patients Receiving Direct-Acting Antiviral Therapies (DAAs)
por: Ghanem, Samar, et al.
Publicado: (2023)

COVID-19 and the prevalence of drug shortages in Canada: a cross-sectional time-series analysis from April 2017 to April 2022
por: Lau, Brian, et al.
Publicado: (2022)

Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data
por: Chen, Zhi-wei, et al.
Publicado: (2016)

292. No association Between Direct-acting Antiviral (DAA) Therapy and Varicella-Zoster Virus (VSV) Reactivation in an Analysis of 37 Prospective Clinical Trials
por: Rohde, Maximilian, et al.
Publicado: (2019)

Role of Inflammatory/Immune Response and Cytokine Polymorphisms in the Severity of Chronic Hepatitis C (CHC) before and after Direct Acting Antiviral (DAAs) Treatment
por: Ferreira, Joana, et al.
Publicado: (2023)

Assessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults
por: Tadrous, Mina, et al.
Publicado: (2021)

Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland
por: Aebi-Popp, Karoline, et al.
Publicado: (2016)

Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study
por: Pereira, Gustavo H., et al.
Publicado: (2022)

Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants
por: Gao, Lulu, et al.
Publicado: (2017)

Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase
por: Hayes, Kaleen N., et al.
Publicado: (2021)

Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
por: Brothers, Sarah, et al.
Publicado: (2022)

EE240 Beyond Symptoms Alleviation: Population-Level Benefits of COVID-19 Oral Direct-Acting Antiviral (DAA) Treatment and Resulting Decreases in Infectivity and Transmission
por: Chacon-Araya, M., et al.
Publicado: (2023)

Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic: A Global Time Series Study
por: Callaway Kim, Katherine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1beagddg6onj70ed2sft9fkp08